Gene therapy

#Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Lead discovery #Regulatory

Phase 1 clinical trial of COVID-19 vaccine begins at University of Queensland

The next critical phase for The University of Queensland’s (UQ) COVID-19 vaccine is underway, with the research effort moving out of the lab and into human trials. Healthy adult volunteers have received the first dose of the vaccine at the Brisbane clinic of phase 1 clinical trials specialist,… Read More

#Covid-19 #News

#Cell therapy #Drug development #Drug discovery #Gene therapy #High Content Screening #Lead discovery #Oncology #RNA

New research model for Cancer Research UK following £300M drop in income

Cancer Research UK is planning to become a leaner, more focused organisation following the impact of COVID-19 on its fundraising income. The charity is making difficult decisions to reduce how much it spends on beating cancer, its operations and the number of staff following… Read More

#Covid-19 #News

#Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell therapy #Clinical trials #Drug discovery #Gene therapy #Imaging #PCR #RNA

LGC expands SARS-CoV-2 molecular solutions to full genome coverage

Image: Fusion Medical Automation Initially designed to target the published CDC and WHO consensus sequences, the AccuPlex SARS-CoV-2 Verification Panel and Reference Material Kit are available with full SARS-CoV-2 viral genome coverage. This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and… Read More

#Covid-19 #News

#Academic #Analysis #Biochemistry #Biologics / Biotechnology #Business #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #High Content Screening #High throughput screening #Immunology / Virology & Vaccines #Lead discovery #Molecular medicine #PCR #Pharmacology #Screening #System biology #Systems biology #Therapeutics

Remotely accessible assays help researchers work from home

Scientists in academic centres and companies around the world desperately search for novel therapeutics and vaccines to treat and prevent COVID-19. However, with lockdowns and limited access to laboratories, researchers are being forced to work from home, putting research continuity at risk. To help scientists continue their R&D,… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Biomarkers #Business #Drug development #Drug discovery #Enabling technologies #Gene therapy #Imaging #Oncology #Preclinical #Translational #Translational chemistry

SCIEX celebrates 50 years of innovation with advanced technology launch

14 July 2020 SCIEX has celebrated its 50th anniversary with a digital product launch. SCIEX virtual product experience introduced products that enable customers to Run Fast, Go Beyond and Power Up. “Half a century ago, SCIEX set out with a mission to develop analytical technologies for aerospace. Today,… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Cell therapy #Drug development #Drug discovery #Gene therapy

Cobra Biologics delivers final plasmids for production of CG01 in epilepsy project

Cobra Biologics has produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy. This completes delivery of all plasmids required to progress to the next phase of the project. The… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical specialities #Clinical trials #Drug discovery #Gene therapy #Imaging #Lead discovery #Precision medicine #RNA

Clinical trial examines alpha-1-antitrypsin for severe COVID-19 infection

Clinician scientists at RCSI University of Medicine and Health Sciences, Ireland, have begun a clinical trial of a promising therapy for critically ill COVID-19 patients in intensive care. In a paper published in the American Journal of Respiratory and Critical Care Medicine, the team, led by RCSI Professors… Read More

#Covid-19 #News

#Cell therapy #Gene editing #Gene therapy #High Content Screening #Stem cells

New paper published on gene editing technique in hematopoietic stem cells

30 June 2020 Image: National Cancer Institute The San Raffaele Telethon Institute for Gene Therapy (SR-Tiget) and Genespire have published data highlighting progress in the development of an improved targeted gene replacement technology in human hematopoietic stem cells (HSCs) in Nature Biotechnology. The paper, entitled Efficient gene editing of… Read More

#News

#Cell therapy #Drug development #Gene therapy #Toxicology

PARP inhibitor could be effective treatment for childhood neuroblastoma

29 June 2020 Image: National Cancer Institute A type of drug already used to treat breast and ovarian cancer, called a PARP inhibitor, may be useful in treating children with high-risk neuroblastoma, a childhood tumour with a low survival rate, a new study suggests. Neuroblastoma is a cancer… Read More

#News

#Biomarkers #Business #Cell therapy #Gene therapy

Stephen Gunstream new Teknova CEO

25 June 2020 Teknova has appointed Stephen Gunstream as chief executive officer. Gunstream has nearly 20 years of experience in the life sciences industry, including positions as Vice President and General Manager for the research and clinical business at BD Biosciences and Chief Commercial Officer at Integrated DNA Technologies. Read More

#News

#AI / data analytics / healthtech / informatics #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Lead discovery #Lead optimisation #Regulatory #Target validation

Avacta positive on evaluation of COVID-19 test strips

Avacta Group has announced that the first Affimer-based rapid test strips to detect SARS-COV-2 spike protein have been developed and evaluated by partners at Cytiva (formerly GE Healthcare Life Sciences) and show positive initial performance data. In mid-May Avacta provided Affimer reagents that are specific to the SARS-COV-2… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Microbiology #RNA #Stem cells #System biology

Taconic Biosciences to distribute critical COVID-19 mouse model

Taconic Biosciences has announced an exclusive agreement with the University of Texas Medical Branch at Galveston (UTMB) to distribute humanised ACE2 mice for coronavirus research. The SARS-CoV-2 virus, which causes COVID-19, uses the ACE2 receptor to enter cells, causing infection. Due to differences between the mouse and human… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Cellular assays #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology #Stem cells

Avacta collaboration offers update on Affimer therapy for COVID-19

Avacta Group, in collaboration with the Centre for Virus Research at the University of Glasgow, has shown that Affimer reagents which bind to the SARS-COV-2 virus spike protein, prevent infection of human cells by a SARS-COV-2 model virus and therefore provide a potential therapy for COVID-19 infection. Avacta… Read More

#Covid-19 #News

#Biologics / Biotechnology #Cell therapy #Clinical trials #Drug development #Drug discovery #Gene therapy #Imaging #Immunology / Virology & Vaccines #RNA

Cobra Biologics signs manufacture agreement with AstraZeneca for COVID-19 vaccine candidate

Cobra Biologics will provide GMP manufacture of the adenovirus vector-based COVID-19 vaccine candidate AZD1222, previously known as ChAdOx1 n-CoV-19. Cobra Biologics, part of the Cognate BioServices family, an international CDMO for biologics and pharmaceuticals, has signed a supply agreement with AstraZeneca UK to provide GMP manufacture of the adenovirus vector-based… Read More

#Covid-19 #News

#Analysis #Biochemistry #Cell therapy #Clinical trials #Gene therapy #Oncology

AstraZeneca presents results from Calquence (acalabrutinib) trials

16 June, 2020 The global science-led biopharmaceutical company said the detailed results from both the Phase II ACE-CL-001 trial and the pivotal Phase III ASCEND trial showed the long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia (CLL), one of the most common types of adult… Read More

#News